keyword
MENU ▼
Read by QxMD icon Read
search

Avastin

keyword
https://www.readbyqxmd.com/read/29772047/swept-source-oct-angiography-identifies-choroidal-neovascularization-arising-from-a-choroidal-nevus
#1
Abed Namavari, Fang Zheng, Elie H Motulsky, João R de Oliveira Dias, Giovanni Gregori, Philip J Rosenfeld
Swept-source optical coherence tomography angiography (SS-OCTA) was used to diagnose choroidal neovascularization (CNV) arising from a choroidal nevus. A 61-year-old woman initially presented with submacular hemorrhage. She was diagnosed with neovascular age-related macular degeneration (AMD) and received three injections of bevacizumab (Avastin; Genentech, South San Francisco, CA). At a follow-up visit, SS-OCTA showed that the CNV appeared to arise from an adjacent choroidal nevus. This is the first report of using SS-OCTA to diagnose CNV associated with a choroidal nevus masquerading as neovascular AMD...
May 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29768958/bevacizumab-induced-atypical-hemolytic-uremic-syndrome-and-treatment-with-eculizumab
#2
Anusha Vakiti, Daulath Singh, Ravi Pilla, Muhamad A Moustafa, Kelly W Fitzpatrick
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye. It is a vascular endothelial growth factor inhibitor which exhibits its action by blocking the growth of blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, and increased risk of infections. Atypical hemolytic uremic syndrome is a serious side effect associated with bevacizumab due to its anti-angiogenic effect...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29743182/fda-s-approval-of-the-first-biosimilar-to-bevacizumab
#3
Sandra J Casak, Steven J Lemery, Jee Chung, Chana Fuchs, Sarah J Schrieber, Edwin C Y Chow, Weishi Yuan, Lisa Rodriguez, Thomas Gwise, Anne Rowzee, Sue Lim, Patricia Keegan, Amy E McKee, Richard Pazdur
Passage of the Biologics Price Competition and Innovation Act of 2009 created an abbreviated licensure pathway for biosimilar products. The Food and Drug Administration approved ABP215 (MVASI, bevacizumab-awwb, Amgen) as a biosimilar to US-licensed Avastin (bevacizumab, Genentech) based on an extensive comparative analytical characterization, data obtained in a pharmacokinetic similarity study in healthy subjects, and a comparative clinical study in patients with non-small cell lung cancer. The totality of the evidence for biosimilarity supported extrapolation of the data to support licensure as a biosimilar for other approved indications of US-licensed Avastin, without the need of additional clinical studies...
May 9, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29715501/pharmacology-study-of-a-chimeric-decoy-receptor-trap-fusion-protein-on-retina-neovascularization-by-dual-blockage-of-vegf-and-fgf-2
#4
Jing Jiang, Ke Xu, Ling Wang, Wei Xin, Guorui Zhao, Min Huang, Shenjun Li, Xuejing Luan, Jianmin Fang
BACKGROUND: Clinical anti-vascular epithelial growth factor (VEGF) therapy trials faced a major challenge due to upregulated expression of other pro-angiogenic factors, such as fibroblast growth factor-2 (FGF-2). RC28, a novel recombinant dual decoy receptor IgG1 Fc-fusion protein, can block VEGFA and FGF-2 simultaneously. It is designed for the treatment of neovascular age-related macular degeneration and other pathological ocular neovascularization. The present study investigated the prevention efficacy of RC28 on choroidal neovascularization (CNV) in a monkey model and compared to the other mono VEGF antagonists; biodistribution and pharmacokinetics performance were also investigated...
April 28, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29670046/resistance-to-anti-angiogenic-therapy-in-cancer-alterations-to-anti-vegf-pathway
#5
REVIEW
Yoshiro Itatani, Kenji Kawada, Takamasa Yamamoto, Yoshiharu Sakai
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy...
April 18, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29664987/congenital-hypertrophy-of-the-retinal-pigment-epithelium-presenting-with-secondary-choroidal-neovascularization
#6
Robert B Garoon, J William Harbour
The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:276-277...
April 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29664980/frequency-of-bevacizumab-and-ranibizumab-injections-for-diabetic-macular-edema-in-medicare-beneficiaries
#7
Connie M Wu, Annie M Wu, Paul B Greenberg, Fei Yu, Flora Lum, Anne L Coleman
BACKGROUND AND OBJECTIVE: To describe the frequency and variation of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) use for diabetic macular edema (DME) in the United States. PATIENTS AND METHODS: The authors obtained a 5% sample of Medicare beneficiaries from the Medicare Part B claims files from 2010 to 2013 and identified beneficiaries with DME using the ICD-9-CM code (362...
April 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29657767/graph-analysis-of-cell-clusters-forming-vascular-networks
#8
A P Alves, O N Mesquita, J Gómez-Gardeñes, U Agero
This manuscript describes the experimental observation of vasculogenesis in chick embryos by means of network analysis. The formation of the vascular network was observed in the area opaca of embryos from 40 to 55 h of development. In the area opaca endothelial cell clusters self-organize as a primitive and approximately regular network of capillaries. The process was observed by bright-field microscopy in control embryos and in embryos treated with Bevacizumab (Avastin® ), an antibody that inhibits the signalling of the vascular endothelial growth factor (VEGF)...
March 2018: Royal Society Open Science
https://www.readbyqxmd.com/read/29652061/bevacizumab-and-near-infrared-probe-conjugated-iron-oxide-nanoparticles-for-vascular-endothelial-growth-factor-targeted-mr-and-optical-imaging
#9
Run Lin, Jing Huang, Liya Wang, Yuancheng Li, Malgorzata Lipowska, Hui Wu, Jianyong Yang, Hui Mao
Vascular endothelial growth factor (VEGF) plays a pivotal role in the cascade of development and progression of cancers. Targeting this cancer hallmark is a logical strategy for imaging based cancer detection and monitoring the anti-angiogenesis treatment. Using Bevacizumab (Avastin®), which is a recombinant humanized monoclonal antibody directly against VEGF and an angiogenesis inhibitor, as a targeting ligand, a multimodal VEGF targeted molecular imaging probe was developed by conjugating near infrared dye (NIR830) labeled bevacizumab to magnetic iron oxide nanoparticles (IONP) for optical and magnetic resonance (MR) imaging of cancers over-expressing VEGF...
April 13, 2018: Biomaterials Science
https://www.readbyqxmd.com/read/29649432/nitric-oxide-signaling-regulates-tumor-induced-intussusceptive-like-angiogenesis
#10
Selvaraj Vimalraj, Srinivasan Bhuvaneswari, Sundaresan Lakshmikirupa, Ganesh Jyothsna, Suvro Chatterjee
Existing animal models for screening tumor angiogenic process have various setbacks that necessitate further investigations. In this study, we developed an ex-ovo egg yolk angiogenesis model to screen the angiogenic potency of tumor cells (HeLa and SiHa cell lines). The egg yolk angiogenesis assay was applied to study the nitric oxide (NO) influence on switching from sprouting angiogenesis (SA) to intussusceptive angiogenesis (IA) under tumor microenvironment. Morphological analysis and SA-like or IA-like markers expression were determined during the development of chicken chorioallantoic membrane (CAM) from day 5 to 13...
April 9, 2018: Microvascular Research
https://www.readbyqxmd.com/read/29643911/pars-plana-vitrectomy-in-vitreous-hemorrhage-with-or-without-intravitreal-bevacizumab-a-comparative-overview
#11
Syed Muhammad Faisal, Muhammad Ali Tahir, Alyscia Miriam Cheema, Muhammad Ijaz Anjum
Objective: To compare the success in patients having vitreous hemorrhage undergoing pars plana vitrectomy with or without preoperative intravitreal injection of Bevacizumab. Methods: This Randomized controlled trial was conducted at Department of Ophthalmology, Jinnah Postgraduate Medical Centre. Karachi. Duration of study was six months from January 2010 to June 2010. In this study 56 patients of advanced diabetic eye disease were divided into two groups. Patients in Group-A underwent three ports pars plana vitrectomy with preoperative intravitreal injection of Bevacizumab (Avastin) 1...
January 2018: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29643797/uneventful-anterior-migration-of-intravitreal-ozurdex-implant-in-a-patient-with-iris-sutured-intraocular-lens-and-descemet-stripping-automated-endothelial-keratoplasty
#12
Andleeb Zafar, Ioannis M Aslanides, Vasileios Selimis, Konstantinos I Tsoulnaras, David Tabibian, George D Kymionis
Purpose: We report here the case of a patient with anterior segment migration of intravitreal dexamethasone implant as well as its management and outcome. Methods: The patient had the following sequence of events: complicated cataract surgery, iris-sutured intraocular lens implant, followed by cystoid macular edema treated with intravitreal Avastin, retinal vein occlusion treated with intravitreal dexamethasone implant, corneal decompensation treated with Descemet stripping automated endothelial keratoplasty (DSAEK), and finally recurrence of macular edema treated with repeated intravitreal dexamethasone implant...
January 2018: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29617713/bevacizumab-may-improve-quality-of-life-but-not-overall-survival-in-glioblastoma-an-epidemiological-study
#13
D Gramatzki, P Roth, E J Rushing, J Weller, N Andratschke, S Hofer, D Korol, L Regli, A Pangalu, M Pless, J Oberle, R Bernays, H Moch, S Rohrmann, M Weller
Background: The vascular endothelial growth factor antibody bevacizumab (Avastin®), received approval for the treatment of recurrent glioblastoma in many countries including the US and Switzerland, but not the European Union, in 2009. Here we explored the hypothesis that the approval of bevacizumab improved outcome with glioblastoma on a population level. Patients and methods: The prognostic significance of epidemiological, molecular genetic, and clinical data including treatment for glioblastoma patients diagnosed from 2010-2014 in the Canton of Zurich, Switzerland, was retrospectively analyzed using log rank test and Cox proportional hazards models...
March 30, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29507055/antitumor-activity-of-dlx1008-an-anti-vegfa-antibody-fragment-with-low-picomolar-affinity-in-human-glioma-models
#14
Emese Szabó, Douglas J Phillips, Miriam Droste, Andrea Marti, Titus Kretzschmar, Abdijapar Shamshiev, Michael Weller
Angiogenesis mediated by vascular endothelial growth factor (VEGF) is a hallmark of glioblastoma. Based on the response rate and improved progression-free survival, although not on overall survival, the 149-kDa anti-VEGF-A IgG antibody bevacizumab (Avastin) has been approved in the United States and Japan for recurrent glioblastoma and in Japan for newly diagnosed glioblastoma; however, it is not approved in the EU. Here we characterize the biologic activity of DLX1008, a 26-kDa anti-VEGF-A single-chain antibody fragment that shows 30-fold stronger affinity to human VEGF-A than bevacizumab...
May 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29492680/formulation-stabilization-and-disaggregation-of-bevacizumab-ranibizumab-and-aflibercept-in-dilute-solutions
#15
Steven A Giannos, Edward R Kraft, Zhen-Yang Zhao, Kevin H Merkley, Jiyang Cai
PURPOSE: Studies were conducted to investigate dilute solutions of the monoclonal antibody (mAb) bevacizumab, mAb fragment ranibizumab and fusion protein aflibercept, develop common procedures for formulation of low concentration mAbs and identify a stabilizing formulation for anti-VEGF mAbs for use in in vitro permeation studies. METHODS: Excipient substitutions were screened. The most stabilizing formulation was chosen. Standard dilutions of bevacizumab, ranibizumab and aflibercept were prepared in PBS, manufacturer's formulation, and the new formulation...
February 28, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29449964/consequences-of-inadvertent-intravitreal-mitomycin-c-injection
#16
Ahmad Mirshahi, Alireza Lashay, Mohammad Reza Mehrabi Bahar, Mojtaba Abrishami
Background: Mitomycin C (MMC) as an alkylating agent is miscellaneous an antineoplastic, antibiotic and ophthalmic agent. Here we aim to report a case of inadvertent intravitreal MMC injection instead of Avastin in case of diabetic macular edema. Case presentation: A 53 years old woman was planned to receive intravitreal Avastin injection, but accidentally, 0.05 ml of MMC 0.2% was injected. Best corrected visual acuity (BCVA) was 20/160 before injection. After 2 days, patient was referred to a tertiary referral eye center...
2018: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/29443362/outcomes-of-intravitreal-bevacizumab-and-diode-laser-photocoagulation-for-treatment-warranted-retinopathy-of-prematurity
#17
Tiffany A Chen, Ira H Schachar, Darius M Moshfeghi
BACKGROUND AND OBJECTIVE: To investigate the outcomes of infants with treatment-warranted retinopathy of prematurity (TW-ROP) who received intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) (IVB) injections as compared to diode laser photocoagulation (DLP). PATIENTS AND METHODS: Data from the Stanford University Network for Diagnosis of Retinopathy of Prematurity database and inpatients at Stanford Children's Hospital were retrospectively reviewed for premature newborns with TW-ROP treated with DLP or 0...
February 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29392857/competitive-affinity-release-for-long-term-delivery-of-antibodies-from-hydrogels
#18
Vincent Huynh, Ryan G Wylie
With increased clinical use of antibodies, long-term delivery strategies are needed to decrease injection frequency and improve health outcomes. A three-component drug-delivery system was developed for competitive affinity release of a streptavidin-antibody conjugate from agarose-desthiobiotin hydrogels via controlled dissolution of sparingly soluble biotin derivatives. The antibody conjugate was localized in the hydrogel through streptavidin-desthiobiotin complexation. Dissolution of sparingly soluble biotin derivatives disrupts streptavidin-desthiobiotin complexation for controlled release of the antibody conjugate...
March 19, 2018: Angewandte Chemie
https://www.readbyqxmd.com/read/29324931/vitrectomy-with-fibrovascular-membrane-delamination-for-proliferative-diabetic-retinopathy-with-or-without-preoperative-avastin
#19
E Papavasileiou, M Vasalaki, C Garnavou-Xirou, S Velissaris, V Zygoura, D McHugh, T L Jackson
OBJECTIVE: To describe and compare 1. The changes in intraretinal microstructure using serial spectral domain optical coherence tomography (SD-OCT) preceding and following pars plana vitrectomy and delamination of fibrovascular membranes and 2. Intraoperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR) who had preoperative Avastin (group A) or not (group B). SUBJECTS AND METHOD: This retrospective, interventional case series includes 113 eyes...
September 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29304269/hemorrhagic-ischemic-retinal-vasculitis-and-alopecia-areata-as-a-manifestation-of-hla-b27
#20
Ravi Sharma, Sandeep Randhawa
A 12-year-old Indian boy presented with acute and severe vision loss in his right eye. He was being treated for scalp alopecia areata and rashes behind the ears and above the brow. The eye examination revealed unilateral hemorrhagic retinal vasculitis. The lab work was normal except for a positive HLA-B27 result. The patient was treated with intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) and systemic immunosuppression. The retinal vasculitis improved with treatment, but visual acuity only mildly improved...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"